These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 17954553

  • 1. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia.
    Janssens B, Raleigh B, Soeung S, Akao K, Te V, Gupta J, Vun MC, Ford N, Nouhin J, Nerrienet E.
    Pediatrics; 2007 Nov; 120(5):e1134-40. PubMed ID: 17954553
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.
    Pediatrics; 2007 Oct; 120(4):e856-61. PubMed ID: 17846147
    [Abstract] [Full Text] [Related]

  • 3. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.
    Clin Infect Dis; 2007 Feb 01; 44(3):447-52. PubMed ID: 17205457
    [Abstract] [Full Text] [Related]

  • 4. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T, Nagappan V, Cinti S, Wei W, Kazanjian P.
    Clin Infect Dis; 2007 Oct 15; 45(8):1085-92. PubMed ID: 17879930
    [Abstract] [Full Text] [Related]

  • 5. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW, Hogg RS, Yip B, Montaner JS, Harrigan PR, Brumme CJ.
    HIV Med; 2007 Jul 15; 8(5):267-70. PubMed ID: 17561871
    [Abstract] [Full Text] [Related]

  • 6. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB, Berrisford AE, Boulle AM.
    Pediatr Infect Dis J; 2008 Nov 15; 27(11):993-8. PubMed ID: 18818556
    [Abstract] [Full Text] [Related]

  • 7. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.
    AIDS; 2008 Jul 11; 22(11):1305-12. PubMed ID: 18580610
    [Abstract] [Full Text] [Related]

  • 8. Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment.
    Ségéral O, Limsreng S, Nouhin J, Hak C, Ngin S, De Lavaissière M, Goujard C, Taburet AM, Nerrienet E, Delfraissy JF, Ouk V, Dulioust A.
    AIDS Res Hum Retroviruses; 2011 Jun 11; 27(6):597-603. PubMed ID: 21083413
    [Abstract] [Full Text] [Related]

  • 9. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S, Larrú B, Maria Bellón J, Resino R, de José MI, Navarro M, Léon JA, Ramos JT, Mellado MJ, Muñoz-Fernández MA.
    BMC Infect Dis; 2006 Jul 11; 6():107. PubMed ID: 16834769
    [Abstract] [Full Text] [Related]

  • 10. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.
    BMC Pediatr; 2007 Mar 17; 7():13. PubMed ID: 17367540
    [Abstract] [Full Text] [Related]

  • 11. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
    Scherpbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, Kuijpers TW.
    Pediatrics; 2006 Mar 17; 117(3):e528-36. PubMed ID: 16481448
    [Abstract] [Full Text] [Related]

  • 12. Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.
    Mihăilescu R, Arama V, Paraschiv S, Streinu-Cercel A, Oţelea D, Munteanu D, Iosipenco M, Chiotan C, Benea OE, Mărdărescu M, Rădulescu M, Hristea A, Ungurianu R, Aramă SS, Cercel AS, Călin R, Băicuş C.
    Rom J Intern Med; 2008 Mar 17; 46(4):305-11. PubMed ID: 19480296
    [Abstract] [Full Text] [Related]

  • 13. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
    Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V.
    HIV Med; 2008 May 17; 9(5):317-21. PubMed ID: 18331562
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 15. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.
    Lindsey JC, Malee KM, Brouwers P, Hughes MD, PACTG 219C Study Team.
    Pediatrics; 2007 Mar 13; 119(3):e681-93. PubMed ID: 17296781
    [Abstract] [Full Text] [Related]

  • 16. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Mar 13; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
    Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V.
    Pediatr Infect Dis J; 2009 Mar 13; 28(3):246-8. PubMed ID: 19165130
    [Abstract] [Full Text] [Related]

  • 18. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 13; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 19. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
    Seyler C, Adjé-Touré C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D, Nolan M, Toure S, Anglaret X.
    AIDS; 2007 May 31; 21(9):1157-64. PubMed ID: 17502726
    [Abstract] [Full Text] [Related]

  • 20. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW.
    Pediatrics; 2006 Aug 31; 118(2):e315-22. PubMed ID: 16847077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.